Preliminary Program
Stream 2: Immuno-Oncology
|
Forum 2-1: Cancer Vaccines |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Yan Leyfman, Director of Immunology Division, WACEM-ACAIM COVID-19 Taskforce, USA |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-2: Breaking Research in Immuno-Oncology Targets |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-3: Checkpoint Blockade, TIGIT, PD-L1/PD-L1 |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-4: Novel Anticancer Antibodies |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Title: TBD Dr. Laura Bover, Director Monoclonal Antibody Core Facility, University of Texas M.D.Anderson Cancer Center, USA
|
|
14:05-14:30 |
Title: Bispecific Nanobody for Cancer Immunotherapy Dr. Seung-Yong Seong, Department of Microbiology and Immunology, Wide River Institute of Immunology, Seoul National University College of Medicine, Korea
|
|
14:30-14:55 |
Speech Opportunity Available |
|
14:55-15:20 |
Speech Opportunity Available |
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Speech Opportunity Available |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-5: Adoptive Cell Therapy, CARs, TILs, TCRs and CAR T’s Dysfunction |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Title: Overcoming the Immune Barrier for "off the shel" Allogeneic CAR T Cells Dr. Sonja Schrepfer, Professor of Surgery, University of California San Francisco, USA
|
|
14:05-14:30 |
Title: TBD Dr. Heinz Lubenau, CEO, Vaximm AG, Germany
|
|
14:30-14:55 |
Title: TBD Dr. Manel Juan, Head of Seccion of Immunopathology, SJD Barcelona Children’s Hospital and Hospital Clínic, Spain
|
|
14:55-15:20 |
Title: TBD Dr. Zhenlong Ye, Director, Shanghai Baize Medical Laboratory, Shanghai Engineering Research Center for Cell Therapy, China
|
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Speech Opportunity Available |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-6: IO Biomarkers |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Speech Opportunity Available |
|
14:05-14:30 |
Speech Opportunity Available |
|
14:30-14:55 |
Speech Opportunity Available |
|
14:55-15:20 |
Speech Opportunity Available |
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Speech Opportunity Available |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-7: Oncolytic Virus Immunotherapy |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Ashok Srivastava, Chief Medical officer, Immuno-Oncology, Hematology and Oncolytic Virus Therapy, Trans Atlantic Therapeutics, USA |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:15 |
Title: Personalized Immune Therapy of Human Cancer Patients with Oncolytic Vaccinia Virus Infected , Autologous Stem Cell Implants Dr. Aladar A. Szalay, Professor, University of Wuerzburg, Germany
|
|
09:15-09:40 |
Combination with Anti-PD-L1 and Paclitaxel and Its Response Dr. Ashok Srivastava, Chief Medical officer, Immuno-Oncology, Hematology and Oncolytic Virus Therapy, Trans Atlantic Therapeutics, USA
|
|
09:40-10:05 |
Speech Opportunity Available |
|
10:05-10:30 |
Speech Opportunity Available |
|
10:30-10:45 |
Coffee Break |
|
10:45-11:10 |
Speech Opportunity Available |
|
11:10-11:35 |
Speech Opportunity Available |
|
11:35-12:00 |
Speech Opportunity Available |
|
12:00-12:25 |
Speech Opportunity Available |
|
Forum 2-8: IO Therapy Combination and Cancer Vaccine |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-9: Next Generation Cancer Immunotherapy and Translational Medicine |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
Contact Us: Email:Mandy@bitcongress.com
Company Name: 3F, Building 2, Dalian Life Science Innovation Center, 43 Huoju Road,
Hi-tech Industrial Zone, Dalian City, Liaoning Province, China
Copyright © 2008-2022 BIT Congress